Aug 22, 2025
https://hallbook.com.br/blogs/693242/RNA-Therapeutics-Market-Growth-Accelerates-Amid-Rising-Innovations
seen from T1
seen from Germany
seen from Germany
seen from T1
seen from United States
seen from United Kingdom
seen from Australia
seen from Georgia
seen from T1
seen from T1
seen from France
seen from Brazil
seen from Australia
seen from United States
seen from Angola
seen from Spain
seen from China
seen from Georgia
seen from United States
seen from France
https://hallbook.com.br/blogs/693242/RNA-Therapeutics-Market-Growth-Accelerates-Amid-Rising-Innovations
Investor Alert: Why the Gene Silencing Market Could Be the Next Big Thing
Introduction
The global gene silencing market is experiencing unprecedented growth, driven by advancements in genetic research, increasing prevalence of genetic disorders, and the rising adoption of gene-silencing technologies in therapeutics and drug discovery. Valued at approximately USD 3.7 billion in 2024, the gene silencing market is projected to expand at a CAGR of over 17.6% from 2025 to 2032, reaching a valuation exceeding USD 15.9 billion by the end of the forecast period. This rapid expansion is fueled by the increasing demand for RNA interference (RNAi), CRISPR-based therapies, and antisense oligonucleotides (ASOs) for targeted gene modulation.
Breakthroughs in gene-editing tools, AI-driven bioinformatics, and nanoparticle-based delivery systems are accelerating innovation and adoption. The use of gene silencing in treating cancer, neurological disorders, and rare genetic diseases, alongside the expansion of personalized medicine and cell and gene therapy applications, continues to strengthen market growth. Additionally, strategic partnerships between biotech firms, pharmaceutical companies, and research institutions are propelling advancements in gene-based therapies.
Request Sample Report PDF (including TOC, Graphs & Tables): https://www.statsandresearch.com/request-sample/40640-global-gene-silencing-market
Gene Silencing Market Dynamics
Key Drivers
Growing Adoption of Gene Silencing in Therapeutics
Increasing application of RNAi, CRISPR-Cas9, and ASOs in gene therapy.
Expansion of precision medicine initiatives leveraging gene silencing for personalized treatment.
Rising Prevalence of Genetic Disorders and Cancer
Escalating demand for innovative treatments for hereditary diseases, cancer, and neurodegenerative disorders.
Emerging gene silencing applications in rare genetic conditions and metabolic disorders.
Advancements in Gene-Editing Technologies
Enhancements in CRISPR-Cas systems for precise genetic modifications.
AI-driven bioinformatics for target identification and therapeutic development.
Strategic Collaborations and Investments in R&D
Increased funding for gene therapy research from public and private sectors.
Expansion of contract research organizations (CROs) and biotech partnerships.
Get up to 30%-40% Discount: https://www.statsandresearch.com/check-discount/40640-global-gene-silencing-market
Gene Silencing Market Challenges
Regulatory and Ethical Constraints
Stringent guidelines governing gene-editing technologies.
Ethical concerns regarding genetic modifications and long-term effects.
Complexities in Gene Delivery Mechanisms
Challenges associated with targeted delivery and minimizing off-target effects.
Development of safe and efficient non-viral and nanoparticle-based delivery systems.
Gene Silencing Market Segmentation
By Technology
RNA Interference (RNAi) – Dominating with a 45.6% gene silencing market share in 2024, growing at a CAGR of 18.4%.
CRISPR-Cas9 – Fastest-growing segment at a CAGR of 21.2%.
Antisense Oligonucleotides (ASOs) – Significant adoption in genetic therapeutics.
DNA Methylation-Based Silencing – Emerging applications in epigenetic modifications.
By Delivery Method
Nanoparticle-Based Delivery – Leading with a 42.7% market share, growing at 19.6% CAGR.
Viral Vector-Based Delivery – Expanding at a CAGR of 18.9%.
Electroporation & Physical Delivery Methods – Increasing adoption in clinical applications.
Chemical Delivery Methods – Advancements in stability and efficacy.
By Disease Type
Cancer – Leading with a 38.9% market share, projected to grow at a CAGR of 19.7%.
Neurodegenerative Diseases – Fastest-growing at a CAGR of 20.3%.
Hereditary and Infectious Diseases – Expanding clinical applications.
Cardiovascular Diseases and Others – Rising demand for novel gene therapies.
By Application
Therapeutics – Dominating with a 60.4% market share, growing at 19.9% CAGR.
Research & Development – Expanding as biotech firms invest in preclinical research.
By End-User
Biotechnology & Pharmaceutical Companies – Holding a 48.7% market share, growing at 18.8% CAGR.
Academic & Research Institutes – Increasing focus on CRISPR-based studies.
Contract Research Organizations (CROs) – Expanding service offerings.
Hospitals & Diagnostic Centers – Rising adoption of gene silencing diagnostics.
By Region
North America – Leading with a 46.2% market share, fueled by R&D investments and regulatory approvals.
Asia Pacific – Fastest-growing at a CAGR of 20.8%, driven by biotech innovations in China, Japan, and India.
Europe, South America, and Middle East & Africa – Steady market expansion.
Competitive Landscape
Key industry players include:
Alnylam Pharmaceuticals – Expanding RNAi-based therapeutic portfolio.
Benitec Biopharma Inc. – Partnering for next-generation RNAi therapies.
Phio Pharmaceuticals – Advancing RNAi-based cancer immunotherapy.
Avidity Biosciences, Riboxx GmbH, Integrated DNA Technologies (IDT), Dyne Therapeutics, Bit Bio, Comanche Biopharma, Thermo Electron Corporation, Temasek Life Sciences Laboratory Ltd., WuXi AppTec – Innovating in RNA-based therapeutics and strategic collaborations.
Emerging Trends and Future Outlook
Key Gene Silencing Market Trends
Expansion of Personalized Gene Therapies – Advancements in tailored treatments based on genetic profiling.
AI-Driven Drug Discovery – Integration of machine learning for gene target identification.
Development of Non-Viral Delivery Methods – Enhancing safety and efficiency.
CRISPR-Based Diagnostics and Therapeutics – Rapidly evolving applications in precision medicine.
Blockchain for Genetic Data Security – Addressing concerns related to data privacy and patient confidentiality.
Purchase Exclusive Report: https://www.statsandresearch.com/enquire-before/40640-global-gene-silencing-market
Future Projections
With continued advancements in genetic research, evolving regulatory frameworks, and increasing global investments in genomic medicine, the gene silencing market is set for sustained expansion. Companies investing in breakthrough RNA-based therapeutics, innovative gene-editing tools, and AI-driven bioinformatics will lead the next phase of growth. As clinical trial success rates improve and new partnerships emerge, gene silencing technologies will play an integral role in reshaping the future of medicine.
Our Services:
On-Demand Reports: https://www.statsandresearch.com/on-demand-reports
Subscription Plans: https://www.statsandresearch.com/subscription-plans
Consulting Services: https://www.statsandresearch.com/consulting-services
ESG Solutions: https://www.statsandresearch.com/esg-solutions
Contact Us:
Stats and Research
Email: [email protected]
Phone: +91 8530698844
Website: https://www.statsandresearch.com
The Impact of Caenorhabditis elegans in Scientific Research
The Remarkable Impact of C. elegans in Scientific Research When scientists are honored with the Nobel Prize in Physiology or Medicine, it is customary for them to express gratitude towards their families, colleagues, and the institutions or funding bodies that supported their research endeavors. This year, as the renowned molecular biologist Gary Ruvkun accepted the pinnacle of recognition in his…
HETEROLOGOUS PROTEINS IN PLANTS
HETEROLOGOUS PROTEINS IN PLANTS
Heterologous proteins: In vivo production of protein is a very complex process, which also involves post-translational modifications of protein, required for its stability and biological activity: like glycosylation, phosphorylation, and proper folding. Protein synthesis is a tightly regulated process involving many enzymes and co-factors at various steps. Production of a protein outside of its…
View On WordPress
GENE SILENCING BY METHYLATION RATHER THAN BY GENE MUTATION
GENE SILENCING BY METHYLATION RATHER THAN BY GENE MUTATION
RESEARCH PROJECT TOPIC ON GENE SILENCING BY METHYLATION RATHER THAN BY GENE MUTATION
TABLE OF CONTENT
Title Page———i
Certification——–ii
Dedication———iii
Acknowledgement——-iv
Abstract ———vi
Table of Content——–vii
Chapter One
1.0 Introduction ——-1
1.1 Statement of Problem——4
1.2 Purpose of the Study——5
1.3 Significance of Study——8
1.4 Limitation——–9
1.5 Scope of Study——-11
Chapter Two
2.0 Review of…
View On WordPress
BioAdvisers said on Biotech Advisers
Multiplexed precision genome editing with trackable genomic barcodes in yeast
Content introduction:
High-throughput creation and functional profiling of DNA sequence variant libraries using CRISPR–Cas9 in yeast
Multiplexed precision genome editing with trackable genomic barcodes in yeast
Secure genome-wide association analysis using multiparty computation
Genome-scale engineering of Saccharomyces cerevisiae with single-nucleotide precision
Reversal of siRNA-mediated gene silencing in vivo
1. High-throughput creation and functional profiling of DNA sequence variant libraries using CRISPR–Cas9 in yeast Construction and characterization of large genetic variant libraries is essential for understanding genome function, but remains challenging. Here, Xiaoge Guo at Wyss Institute for Biologically Inspired Engineering at Harvard University in Boston, Massachusetts, USA and his colleagues introduce a Cas9-based approach for generating pools of mutants with defined genetic alterations (deletions, substitutions, and insertions) with an efficiency of 80–100% in yeast, along with methods for tracking their fitness en masse. They demonstrate the utility of their approach by characterizing the DNA helicase SGS1 with small tiling deletion mutants that span the length of the protein and a series of point mutations against highly conserved residues in the protein. In addition, they created a genome-wide library targeting 315 poorly characterized small open reading frames (smORFs, <100 amino acids in length) scattered throughout the yeast genome, and assessed which are vital for growth under various environmental conditions. Their strategy allows fundamental biological questions to be investigated in a high-throughput manner with precision.
Read more, please click https://www.nature.com/articles/nbt.4147
2. Multiplexed precision genome editing with trackable genomic barcodes in yeast Our understanding of how genotype controls phenotype is limited by the scale at which we can precisely alter the genome and assess the phenotypic consequences of each perturbation. Here Kevin R Roy at Stanford University in Palo Alto, California, USA and his colleagues describe a CRISPR–Cas9-based method for multiplexed accurate genome editing with short, trackable, integrated cellular barcodes (MAGESTIC) in Saccharomyces cerevisiae. MAGESTIC uses array-synthesized guide–donor oligos for plasmid-based high-throughput editing and features genomic barcode integration to prevent plasmid barcode loss and to enable robust phenotyping. They demonstrate that editing efficiency can be increased more than fivefold by recruiting donor DNA to the site of breaks using the LexA–Fkh1p fusion protein. They performed saturation editing of the essential gene SEC14 and identified amino acids critical for chemical inhibition of lipid signaling. They also constructed thousands of natural genetic variants, characterized guide mismatch tolerance at the genome scale, and ascertained that cryptic Pol III termination elements substantially reduce guide efficacy. MAGESTIC will be broadly useful to uncover the genetic basis of phenotypes in yeast.
Read more, please click https://www.nature.com/articles/nbt.4137
3. Secure genome-wide association analysis using multiparty computation Most sequenced genomes are currently stored in strict access-controlled repositories. Free access to these data could improve the power of genome-wide association studies (GWAS) to identify disease-causing genetic variants and aid the discovery of new drug targets. However, concerns over genetic data privacy may deter individuals from contributing their genomes to scientific studies and could prevent researchers from sharing data with the scientific community. Although cryptographic techniques for secure data analysis exist, none scales to computationally intensive analyses, such as GWAS. Here Hyunghoon Cho at Massachusetts Institute of Technology in Cambridge, Massachusetts, USA and his colleagues describe a protocol for large-scale genome-wide analysis that facilitates quality control and population stratification correction in 9K, 13K, and 23K individuals while maintaining the confidentiality of underlying genotypes and phenotypes. They show the protocol could feasibly scale to a million individuals. This approach may help to make currently restricted data available to the scientific community and could potentially enable secure genome crowdsourcing, allowing individuals to contribute their genomes to a study without compromising their privacy.
Read more, please click https://www.nature.com/articles/nbt.4108
4. Genome-scale engineering of Saccharomyces cerevisiae with single-nucleotide precision Zehua Bao at University of Illinois at Urbana-Champaign in Urbana, Illinois, USA and his colleagues developed a CRISPR–Cas9- and homology-directed-repair-assisted genome-scale engineering method named CHAnGE that can rapidly output tens of thousands of specific genetic variants in yeast. More than 98% of target sequences were efficiently edited with an average frequency of 82%. They validate the single-nucleotide resolution genome-editing capability of this technology by creating a genome-wide gene disruption collection and apply their method to improve tolerance to growth inhibitors.
Read more, please click https://www.nature.com/articles/nbt.4132
5. Reversal of siRNA-mediated gene silencing in vivo Ivan Zlatev at Alnylam Pharmaceuticals in Cambridge, Massachusetts, USA and his colleagues report rapid, potent reversal of GalNAc-siRNA-mediated RNA interference (RNAi) activity in vivo with short, synthetic, high-affinity oligonucleotides complementary to the siRNA guide strand. They found that 9-mers with five locked nucleic acids (LNAs) have the highest potency across several targets. Their modular, sequence-specific approach, named REVERSIR, may enhance the therapeutic profile of any long-acting GalNAc–siRNA (short interfering RNA) conjugate by enabling control of RNAi pharmacology.
Read more, please click https://www.nature.com/articles/nbt.4136
New Post has been published on Biotech Advisers
New Post has been published on http://www.bioadvisers.com/multiplexed-precision-genome-editing-with-trackable-genomic-barcodes-in-yeast/
Multiplexed precision genome editing with trackable genomic barcodes in yeast
Content introduction:
High-throughput creation and functional profiling of DNA sequence variant libraries using CRISPR–Cas9 in yeast
Multiplexed precision genome editing with trackable genomic barcodes in yeast
Secure genome-wide association analysis using multiparty computation
Genome-scale engineering of Saccharomyces cerevisiae with single-nucleotide precision
Reversal of siRNA-mediated gene silencing in vivo
1. High-throughput creation and functional profiling of DNA sequence variant libraries using CRISPR–Cas9 in yeast Construction and characterization of large genetic variant libraries is essential for understanding genome function, but remains challenging. Here, Xiaoge Guo at Wyss Institute for Biologically Inspired Engineering at Harvard University in Boston, Massachusetts, USA and his colleagues introduce a Cas9-based approach for generating pools of mutants with defined genetic alterations (deletions, substitutions, and insertions) with an efficiency of 80–100% in yeast, along with methods for tracking their fitness en masse. They demonstrate the utility of their approach by characterizing the DNA helicase SGS1 with small tiling deletion mutants that span the length of the protein and a series of point mutations against highly conserved residues in the protein. In addition, they created a genome-wide library targeting 315 poorly characterized small open reading frames (smORFs, <100 amino acids in length) scattered throughout the yeast genome, and assessed which are vital for growth under various environmental conditions. Their strategy allows fundamental biological questions to be investigated in a high-throughput manner with precision.
Read more, please click https://www.nature.com/articles/nbt.4147
2. Multiplexed precision genome editing with trackable genomic barcodes in yeast Our understanding of how genotype controls phenotype is limited by the scale at which we can precisely alter the genome and assess the phenotypic consequences of each perturbation. Here Kevin R Roy at Stanford University in Palo Alto, California, USA and his colleagues describe a CRISPR–Cas9-based method for multiplexed accurate genome editing with short, trackable, integrated cellular barcodes (MAGESTIC) in Saccharomyces cerevisiae. MAGESTIC uses array-synthesized guide–donor oligos for plasmid-based high-throughput editing and features genomic barcode integration to prevent plasmid barcode loss and to enable robust phenotyping. They demonstrate that editing efficiency can be increased more than fivefold by recruiting donor DNA to the site of breaks using the LexA–Fkh1p fusion protein. They performed saturation editing of the essential gene SEC14 and identified amino acids critical for chemical inhibition of lipid signaling. They also constructed thousands of natural genetic variants, characterized guide mismatch tolerance at the genome scale, and ascertained that cryptic Pol III termination elements substantially reduce guide efficacy. MAGESTIC will be broadly useful to uncover the genetic basis of phenotypes in yeast.
Read more, please click https://www.nature.com/articles/nbt.4137
3. Secure genome-wide association analysis using multiparty computation Most sequenced genomes are currently stored in strict access-controlled repositories. Free access to these data could improve the power of genome-wide association studies (GWAS) to identify disease-causing genetic variants and aid the discovery of new drug targets. However, concerns over genetic data privacy may deter individuals from contributing their genomes to scientific studies and could prevent researchers from sharing data with the scientific community. Although cryptographic techniques for secure data analysis exist, none scales to computationally intensive analyses, such as GWAS. Here Hyunghoon Cho at Massachusetts Institute of Technology in Cambridge, Massachusetts, USA and his colleagues describe a protocol for large-scale genome-wide analysis that facilitates quality control and population stratification correction in 9K, 13K, and 23K individuals while maintaining the confidentiality of underlying genotypes and phenotypes. They show the protocol could feasibly scale to a million individuals. This approach may help to make currently restricted data available to the scientific community and could potentially enable secure genome crowdsourcing, allowing individuals to contribute their genomes to a study without compromising their privacy.
Read more, please click https://www.nature.com/articles/nbt.4108
4. Genome-scale engineering of Saccharomyces cerevisiae with single-nucleotide precision Zehua Bao at University of Illinois at Urbana-Champaign in Urbana, Illinois, USA and his colleagues developed a CRISPR–Cas9- and homology-directed-repair-assisted genome-scale engineering method named CHAnGE that can rapidly output tens of thousands of specific genetic variants in yeast. More than 98% of target sequences were efficiently edited with an average frequency of 82%. They validate the single-nucleotide resolution genome-editing capability of this technology by creating a genome-wide gene disruption collection and apply their method to improve tolerance to growth inhibitors.
Read more, please click https://www.nature.com/articles/nbt.4132
5. Reversal of siRNA-mediated gene silencing in vivo Ivan Zlatev at Alnylam Pharmaceuticals in Cambridge, Massachusetts, USA and his colleagues report rapid, potent reversal of GalNAc-siRNA-mediated RNA interference (RNAi) activity in vivo with short, synthetic, high-affinity oligonucleotides complementary to the siRNA guide strand. They found that 9-mers with five locked nucleic acids (LNAs) have the highest potency across several targets. Their modular, sequence-specific approach, named REVERSIR, may enhance the therapeutic profile of any long-acting GalNAc–siRNA (short interfering RNA) conjugate by enabling control of RNAi pharmacology.
Read more, please click https://www.nature.com/articles/nbt.4136
Bioadvisers shared on Biotech Advisers
Multiplexed precision genome editing with trackable genomic barcodes in yeast
Content introduction:
High-throughput creation and functional profiling of DNA sequence variant libraries using CRISPR–Cas9 in yeast
Multiplexed precision genome editing with trackable genomic barcodes in yeast
Secure genome-wide association analysis using multiparty computation
Genome-scale engineering of Saccharomyces cerevisiae with single-nucleotide precision
Reversal of siRNA-mediated gene silencing in vivo
1. High-throughput creation and functional profiling of DNA sequence variant libraries using CRISPR–Cas9 in yeast Construction and characterization of large genetic variant libraries is essential for understanding genome function, but remains challenging. Here, Xiaoge Guo at Wyss Institute for Biologically Inspired Engineering at Harvard University in Boston, Massachusetts, USA and his colleagues introduce a Cas9-based approach for generating pools of mutants with defined genetic alterations (deletions, substitutions, and insertions) with an efficiency of 80–100% in yeast, along with methods for tracking their fitness en masse. They demonstrate the utility of their approach by characterizing the DNA helicase SGS1 with small tiling deletion mutants that span the length of the protein and a series of point mutations against highly conserved residues in the protein. In addition, they created a genome-wide library targeting 315 poorly characterized small open reading frames (smORFs, <100 amino acids in length) scattered throughout the yeast genome, and assessed which are vital for growth under various environmental conditions. Their strategy allows fundamental biological questions to be investigated in a high-throughput manner with precision.
Read more, please click https://www.nature.com/articles/nbt.4147
2. Multiplexed precision genome editing with trackable genomic barcodes in yeast Our understanding of how genotype controls phenotype is limited by the scale at which we can precisely alter the genome and assess the phenotypic consequences of each perturbation. Here Kevin R Roy at Stanford University in Palo Alto, California, USA and his colleagues describe a CRISPR–Cas9-based method for multiplexed accurate genome editing with short, trackable, integrated cellular barcodes (MAGESTIC) in Saccharomyces cerevisiae. MAGESTIC uses array-synthesized guide–donor oligos for plasmid-based high-throughput editing and features genomic barcode integration to prevent plasmid barcode loss and to enable robust phenotyping. They demonstrate that editing efficiency can be increased more than fivefold by recruiting donor DNA to the site of breaks using the LexA–Fkh1p fusion protein. They performed saturation editing of the essential gene SEC14 and identified amino acids critical for chemical inhibition of lipid signaling. They also constructed thousands of natural genetic variants, characterized guide mismatch tolerance at the genome scale, and ascertained that cryptic Pol III termination elements substantially reduce guide efficacy. MAGESTIC will be broadly useful to uncover the genetic basis of phenotypes in yeast.
Read more, please click https://www.nature.com/articles/nbt.4137
3. Secure genome-wide association analysis using multiparty computation Most sequenced genomes are currently stored in strict access-controlled repositories. Free access to these data could improve the power of genome-wide association studies (GWAS) to identify disease-causing genetic variants and aid the discovery of new drug targets. However, concerns over genetic data privacy may deter individuals from contributing their genomes to scientific studies and could prevent researchers from sharing data with the scientific community. Although cryptographic techniques for secure data analysis exist, none scales to computationally intensive analyses, such as GWAS. Here Hyunghoon Cho at Massachusetts Institute of Technology in Cambridge, Massachusetts, USA and his colleagues describe a protocol for large-scale genome-wide analysis that facilitates quality control and population stratification correction in 9K, 13K, and 23K individuals while maintaining the confidentiality of underlying genotypes and phenotypes. They show the protocol could feasibly scale to a million individuals. This approach may help to make currently restricted data available to the scientific community and could potentially enable secure genome crowdsourcing, allowing individuals to contribute their genomes to a study without compromising their privacy.
Read more, please click https://www.nature.com/articles/nbt.4108
4. Genome-scale engineering of Saccharomyces cerevisiae with single-nucleotide precision Zehua Bao at University of Illinois at Urbana-Champaign in Urbana, Illinois, USA and his colleagues developed a CRISPR–Cas9- and homology-directed-repair-assisted genome-scale engineering method named CHAnGE that can rapidly output tens of thousands of specific genetic variants in yeast. More than 98% of target sequences were efficiently edited with an average frequency of 82%. They validate the single-nucleotide resolution genome-editing capability of this technology by creating a genome-wide gene disruption collection and apply their method to improve tolerance to growth inhibitors.
Read more, please click https://www.nature.com/articles/nbt.4132
5. Reversal of siRNA-mediated gene silencing in vivo Ivan Zlatev at Alnylam Pharmaceuticals in Cambridge, Massachusetts, USA and his colleagues report rapid, potent reversal of GalNAc-siRNA-mediated RNA interference (RNAi) activity in vivo with short, synthetic, high-affinity oligonucleotides complementary to the siRNA guide strand. They found that 9-mers with five locked nucleic acids (LNAs) have the highest potency across several targets. Their modular, sequence-specific approach, named REVERSIR, may enhance the therapeutic profile of any long-acting GalNAc–siRNA (short interfering RNA) conjugate by enabling control of RNAi pharmacology.
Read more, please click https://www.nature.com/articles/nbt.4136